Skip to main content
TSHA $3.99 -0.25%
TSHA logo
TSHA · Taysha Gene Therapies, Inc.
Track TSHA — free
$3.99 -0.01 (-0.25%) At close · Nov 18 Play latest call Q3 2026 earnings call transcript
Market Cap
$1.30B
Shares
326.05M
Volume · Nov 18 3.55M Avg daily vol (3M) 3.62M
All webcasts

Earnings call · FY2025 Q4

Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call

Concluded Mar 19, 2026
Mar 19, 2026
Period
FY2025 Q4
Runtime
—
Sources
2 artifacts
Revenue · derived Q4 $5.49M +171.3% YoY
Net income · derived Q4 -$27.85M
Open full screen 8-K 10-K

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. 8-K earnings release, 10-K stay in one workspace.

Regulatory Progress with FDA 54 Rett Syndrome Market Opportunity 29 TASHA-102 Clinical Development 21 Manufacturing and CMC Readiness 14 Commercial Readiness 9 Safety and Tolerability 3

Management tone

Confident

Net tone +72 · moderate hedging

Grounding quotes
  • “2025 was a year of significant execution for TASIA”
  • “This progress has set the stage for what we expect to be a transformative year ahead for TASIA”
  • “We remain on track to complete dosing in the second quarter of 2026”
  • “in what we've reported on to date, we've never seen a loss of any gain”

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Full-screen source Call document